As part of the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) program, the efficacy of once-weekly subcutaneous semaglutide was evaluated in over 7,000 patients in six global phase IIIa trials (SUSTAIN 16) across the wide spectrum of the T2D disease course (1621) and in nearly 3,000 patients in four phase IIIb trials (SUSTAIN 710) (2225) ( Table 1 )
Further, histopathology of hepatic tissue showed a reduced expression of caspase-3, cellular apoptosis, exhibiting liver protection [48]
professional input
Lean mass sparing in resistance-trained athletes during caloric restriction: the role of resistance training volume
Importantly, tirzepatide achieved these results with concurrent weight loss, while insulin therapy was associated with weight gain
While this looks like a regulatory win on the surface, it doesn't actually deliver clarity or safety improvements for the much larger population already using these compounds today, Campbell explains